Labcorp Holdings Inc. (NYSE:LH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Labcorp Holdings Inc. (NYSE:LH) have received an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $308.00.

Several equities analysts have recently commented on LH shares. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. JPMorgan Chase & Co. lifted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Robert W. Baird set a $334.00 price objective on shares of Labcorp in a research report on Friday, May 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Piper Sandler raised their target price on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th.

Labcorp Stock Up 1.8%

Labcorp stock opened at $262.96 on Friday. The company’s 50-day moving average price is $263.33 and its two-hundred day moving average price is $265.88. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The stock has a market cap of $21.56 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.81 and a beta of 0.91. Labcorp has a twelve month low of $241.81 and a twelve month high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the business earned $3.84 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, analysts expect that Labcorp will post 17.99 EPS for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio is presently 25.51%.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at approximately $22,613,209.08. This trade represents a 9.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Labcorp

Institutional investors have recently made changes to their positions in the stock. REAP Financial Group LLC lifted its position in shares of Labcorp by 20.4% during the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after purchasing an additional 37 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 40 shares in the last quarter. V Square Quantitative Management LLC grew its holdings in Labcorp by 1.7% during the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 40 shares in the last quarter. Hilltop Holdings Inc. increased its stake in Labcorp by 2.6% during the 4th quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock worth $409,000 after buying an additional 41 shares during the period. Finally, Advisor OS LLC increased its stake in Labcorp by 5.4% during the 3rd quarter. Advisor OS LLC now owns 821 shares of the medical research company’s stock worth $236,000 after buying an additional 42 shares during the period. Institutional investors own 95.94% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.